

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00		A2	(11) International Publication Number: WO 00/62765 (43) International Publication Date: 26 October 2000 (26.10.00)
<p>(21) International Application Number: PCT/GB00/01380</p> <p>(22) International Filing Date: 11 April 2000 (11.04.00)</p> <p>(30) Priority Data: 60/129,901 16 April 1999 (16.04.99) US</p> <p>(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BARLAAM, Bernard, Christophe [FR/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). PISER, Timothy, Martin [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US).</p> <p>(74) Agent: PHILLIPS, Neil, Godfrey, Alasdair, AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	

(54) Title: ESTROGEN RECEPTOR- β LIGANDS

(57) Abstract

A method for treating a disease associated with the estrogen receptor- β , comprising the step of administering a therapeutically effective amount of a compound that satisfies the equation: $(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 1$, optionally having the general structure (I).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ESTROGEN RECEPTOR- β LIGANDS

Technical Field

The present invention is directed to a series of ligands, and more particularly to
5 estrogen receptor- β ligands which have better selectivity than estrogen for the estrogen
receptor- β over the estrogen receptor- α , as well as to methods for their production and use in
the treatment of diseases related to the estrogen receptor- β , specifically, Alzheimer's disease,
anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid
arthritis, or prostate cancer.

Background

Estrogen-replacement therapy ("ERT") reduces the incidence of Alzheimer's disease
and improves cognitive function in Alzheimer's disease patients (Nikолов *et al.* Drugs of
Today, 34(11), 927-933 (1998)). ERT also exhibits beneficial effects in osteoporosis and
cardiovascular disease, and may have anxiolytic and anti-depressant therapeutic properties.

15 However, ERT shows detrimental uterine and breast side effects that limit its use.

The beneficial effects of ERT in post-menopausal human women is echoed by
beneficial effects of estrogen in models relevant to cognitive function, anxiety, depression,
bone loss, and cardiovascular damage in ovariectomized rats. Estrogen also produces uterine
and breast hypertrophy in animal models reminiscent of its mitogenic effects on these tissues
20 in humans.

The beneficial effects of ERT in post-menopausal human women is echoed by
beneficial effects of estrogen in models relevant to cognitive function, anxiety, depression,
bone loss, and cardiovascular damage in ovariectomized rats. Specifically, experimental
studies have demonstrated that estrogen effects the central nervous system ("CNS") by
25 increasing cholinergic function, increasing neurotrophin / neurotrophin receptor expression,
altering amyloid precursor protein processing, providing neuroprotection against a variety of
insults, and increasing glutamatergic synaptic transmission, among other effects. The overall
CNS profile of estrogen effects in pre-clinical studies is consistent with its clinical utility in
improving cognitive function and delaying Alzheimer's disease progression. Estrogen also
30 produces mitogenic effects in uterine and breast tissue indicative of its detrimental side effects
on these tissues in humans.

-2-

The estrogen receptor ("ER") in humans, rats, and mice exists as two subtypes, ER- α and ER- β , which share about a 50% identity in the ligand-binding domain (Kuiper *et al.* Endocrinology 139(10) 4252-4263 (1998)). The difference in the identity of the subtypes accounts for the fact that some small compounds have been shown to bind preferentially to 5 one subtype over the other (Kuiper *et al.*).

In rats, ER- β is strongly expressed in brain, bone and vascular epithelium, but weakly expressed in uterus and breast, relative to ER- α . Furthermore, ER- α knockout (ERKO- α) mice are sterile and exhibit little or no evidence of hormone responsiveness of reproductive tissues. In contrast, ER- β knockout (ERKO- β) mice are fertile, and exhibit normal 10 development and function of breast and uterine tissue. These observations suggest that selectively targeting ER- β over ER- α could confer beneficial effects in several important human diseases, such as Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, and cardiovascular disease without the liability of reproductive system side effects. Selective effects on ER- β -expressing tissues (CNS, bone, etc.) over uterus and breast 15 could be achieved by agents that selectively interact with ER- β over ER- α .


It is a purpose of this invention to identify ER- β -selective ligands that are useful in treating diseases in which ERT has therapeutic benefits.

It is another purpose of this invention to identify ER- β -selective ligands that mimic the beneficial effects of ERT on brain, bone and cardiovascular function.

20 It is another purpose of this invention to identify ER- β -selective ligands that increase cognitive function and delay Alzheimer's disease progression.

Summary of the Invention

This present invention is directed to the use of compounds having the generic structure:



as ER- β -selective ligands, which mimic ERT, but lack undesirable side effects of ERT. These compounds particularly satisfy the formula:

$$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 1,$$

5 preferably:

$$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 30.$$

more preferably:


$$(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 100,$$

10 wherein $K_{i\alpha A}$ is the K_i value for the ligand in ER- α ; $K_{i\beta A}$ is the K_i value for the ligand in ER- β ; $K_{i\alpha E}$ is the K_i value for estrogen in ER- α ; and $K_{i\beta E}$ is the K_i value for estrogen in ER- β .

Detailed Description of the Invention

The instant invention involves a method for treating a disease associated with the estrogen receptor- β , comprising the step of administering a therapeutically-effective amount 15 of a compound that satisfies the equation $(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 1$, wherein $K_{i\alpha A}$ is the K_i value for the agonist in ER- α ; $K_{i\beta A}$ is the K_i value for the agonist in ER- β ; $K_{i\alpha E}$ is the K_i value for estrogen in ER- α ; and $K_{i\beta E}$ is the K_i value for estrogen in ER- β . Preferably, the compound satisfies the equation $(K_{i\alpha A}/K_{i\beta A})/(K_{i\alpha E}/K_{i\beta E}) > 100$. Preferred diseases associated with the estrogen receptor- β are selected from Alzheimer's disease, anxiety disorders, depressive 20 disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer. More preferably, the diseases are Alzheimer's disease or depressive disorders.


The compounds of the instant invention are ER- β -selective ligands of the structure:




-4-

In this structure L^1 is $-C(=O)-$, $=C(R^6)-$, $-CH(R^6)-$, O, S, or NR^a , preferably $-C(=O)-$, $=C(R^6)-$, $-CH(R^6)-$ or O; L^2 is $=C-$ or $-CH-$; L^3 is $=C(R^6)-$, $-CH(R^6)-$ or $-C(=O)-$; and L^4 is $-C(=O)-$, CH_2 , O, S, or NR^a , preferably $-C(=O)-$, CH_2 or O, provided that when L^1 is $-C(=O)-$, L^4 is CH_2 , O, S, or NR^a ; when L^4 is $-C(=O)-$, L^1 is CH_2 , O, S, or NR^a ; and when L^3 is $-C(=O)-$, L^1 is $=C(R^6)-$ or $-CH(R^6)-$, and L^4 is O or NR^a . Additionally, when L^1 is $=C(R^6)-$, L^2 is $=C-$; when L^1 is $-CH(R^6)-$, L^2 is $-CH-$; when L^3 is $=C(R^6)-$, L^2 is $=C-$; and when L^3 is $-CH(R^6)-$, L^2 is $-CH-$. \equiv represents a single bond or double bond, depending upon the hybridization of L^1 - L^4 . The structures for L^2 show only three bonds because the fourth bond is a single bond to R^1 .


R^1 is attached via a single bond to L^2 , and is phenyl, substituted phenyl, Het, or substituted Het, as defined below. R^1 is preferably:



wherein: R^7 is H, Cl, or methyl; R^8 is Br, Cl, F, R^a , OR^a , or allyl; R^9 is H, OH, NH_2 , Br, Cl; and R^{10} is H or methyl; or R^8 and R^9 may combine to be $-OCH_2O-$, forming a secondary 5-membered ring structure exterior to the phenyl group; or R^1 is a substituted or unsubstituted heterocyclic substituent having the following structure:



: more preferably unsubstituted



R^2 , R^3 , R^4 , and R^5 are each, independently, $-R^a$, $-OR^a$, $-SR^a$, $-NR^aR^a$, $-NC(=O)R^a$, $-NS(=O)R^a$, $-NS(=O)_2R^a$, halogen, cyano, $-CF_3$, $-CO_2R^a$, $-C(=O)R^a$, $-C(=O)NHR^a$, nitro, $-S(=O)R^a$, or $-S(=O)_2R^a$, and is preferably R^a , OR^a , NR^a_2 , $NC(=O)R^a$, CF_3 , or halogen, preferably, hydrogen, hydroxyl or methyl.

R^6 is R^a , phenyl or CF_3 .

R^a is, independently, at each occurrence, H or (C_1-C_5) alkyl.


-5-

When L¹ is -C(=O)-, and R² is hydroxy or hydrogen, and R³ is hydrogen, and R⁴ is hydroxy, and R⁵ is hydrogen, and R⁶ is hydrogen, then R¹ is not para-phenol.

For purposes of this invention, "substituted" when used to modify a phenyl or a

heteroatomic ring means such a ring substituted at one or more positions, independently, with
5 -R^a, -OR^a, -SR^a, -NR^aR^a, -NC(=O)R^a, -NS(=O)R^a, -NS(=O)₂R^a, halogen, cyano, -CF₃, -CO₂R^a,
-C(=O)R^a, -C(=O)NHR^a, nitro, -S(=O)R^a, or -S(=O)₂R^a.

Also, for purposes of this invention, "Het" means a substituted or unsubstituted one-
or two-ring heterocycle selected from the following:



10 wherein the crossed bond represents that the heterocycle may be attached at any available position on the ring that it crosses.

Estrogen Receptor Binding Measurements

The ability of a compound to bind to ER was measured by its ability to compete for binding with the radio-labeled estrogen, [¹²⁵I]-16 α -ido-3,17 β -estradiol (NEN, Cat.#NEX-144). The radio-ligand is hereafter referred to as [¹²⁵I]-estradiol.

5 ER- β (Gen Bank Accession #X99101) or ER- α (Gen Bank Accession #M12674) cDNAs were cloned into the expression vector pSG5 (Stratagene), transformed into *e. coli* strain DH α F', and purified using anion-exchange resin columns (Qiagen Cat.#12125). Receptor protein was prepared by *in vitro* transcription and translation of these plasmids using the TNT T7 Quick-Coupled reticulocyte lysate system (Promega Cat.#L1170). Reticulocyte 10 lysate (12.5 mL) was incubated for 90 min at 30 °C with 312.5 μ g of ER- α and 625 μ g of ER- β plasmids. Programmed lysate was then aliquotted and stored frozen at -80 °C.

Compounds were tested in duplicate at half-log concentrations ranging from 10 pM to 15 3 μ M. Compounds were prepared as 1 mM stocks in DMSO, then diluted in the binding-assay buffer (in mM: 20 HEPES, 150 NaCl, 1 EDTA, 6 monothioglycerol and 10 Na₂MoO₄; 10% wt/vol glycerol, and pH = 7.9) to a series of three-fold concentrated, 20 μ L aliquots in a 96-well plate. Receptor aliquots were thawed on ice, and appropriately diluted (see below) in binding assay buffer. Diluted receptor (30 μ L/each) was added to each well. [¹²⁵I]-estradiol was diluted from the manufacturer's ethanol stock solution to a 900 pM working solution in binding-assay buffer. The final assay volume was 60 μ L, consisting of 20 μ L of a compound 20 according to the instant invention, 30 μ L of programmed reticulocyte lysate, and 10 μ L of 900 pM [¹²⁵I]-estradiol. The final concentration of [¹²⁵I]-estradiol was 150 pM. Plates containing the final assay mixture were mixed on a shaker for 2 min and incubated overnight (~16 h) at 4 °C.

Receptor-bound and unbound radioligand was separated by filtration over sephadex 25 columns. Columns (45 μ L bed volume) were prepared by adding dry column media (Pharmacia Cat#G-25) to 96-well column templates (Millipore MultiScreen Plates Cat#MAHVN4510). Columns were then saturated with 300 μ L of binding-assay buffer and stored at 4 °C. Prior to use, stored columns were spun for 10 minutes at 2000 RPM, then washed twice with 200 μ L of fresh binding buffer. The binding-assay mixtures (50 μ L/each) 30 were then applied to the columns, and an additional elution volume of 35 μ L was immediately applied to the column. Receptor-bound radioligand was then eluted from the column by

centrifugation for 10 minutes at 2000 RPM. A scintillation cocktail (145 μ L) was added to the eluted radioligand/receptor complex, and radio-label was measured by liquid scintillation counting.

Non-specific binding was defined by competition with 150 nM diethylstilbestrol

- 5 (DES). Binding affinities are expressed as K_i , calculated using the Cheng-Prushoff formula according to IC_{50} values generated by fitting the relationship of concentration to percent specific binding (SB) with the following equation:

$$\% \text{ SB} = \text{Maximum} - (\text{Maximum} - \text{Minimum}) / (1 + 10^{(\log IC_{50} - \log [\text{Compound}])})$$

In this assay, standard estrogen receptor ligands estradiol and DES were detected as high-

- 10 affinity ($K_i < 1$ nM), non-selective ligands of ER- β and ER- α .

The volume of receptor-programmed reticulocyte lysate to be added to the binding assay was determined independently from two measurements made on each batch of receptor prepared. First, K_i s were determined for standard compounds using a series of dilutions of the receptor preparation. Scatchard analysis of ligand binding affinity was performed at the 15 receptor dilutions that produced reported K_i s for these compounds and an acceptable signal:noise ratio (~10). These experiments indicated a K_D for [^{125}I]-estradiol of 0.1-1 nM, and a B_{max} of 5-30 pmol.

Administration and Use

Compounds of the present invention are shown to have high selectivity for ER- β over

- 20 ER- α , and may possess agonist activity on ER- β without undesired uterine effects. Thus, these compounds, and compositions containing them, may be used as therapeutic agents in the treatment of various CNS diseases related to ER- β , such as, for example, Alzheimer's disease.

The present invention also provides compositions comprising an effective amount of compounds of the present invention, including the nontoxic addition salts, amides and esters 25 thereof, which may, serve to provide the above-recited therapeutic benefits. Such compositions may also be provided together with physiologically-tolerable liquid, gel or solid diluents, adjuvants and excipients. The compounds of the present invention may also be combined with other compounds known to be used as therapeutic agents for the above or other indications.

- 30 These compounds and compositions may be administered by qualified health care professionals to humans in a manner similar to other therapeutic agents and, additionally, to

other mammals for veterinary use, such as with domestic animals. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active ingredient is often mixed with diluents or 5 excipients which are physiologically tolerable and compatible with the active ingredient. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH-buffering agents, and the like.

10 The compositions are conventionally administered parenterally, by injection, for example, either subcutaneously or intravenously. Additional formulations which are suitable for other modes of administration include suppositories, intranasal aerosols, and, in some cases, oral formulations. For suppositories, traditional binders and excipients may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from 15 mixtures containing the active ingredient. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained-release formulations, or powders.

20 The present compounds may be formulated into the compositions as neutral or salt forms. Pharmaceutically-acceptable nontoxic salts include the acid addition salts (formed with the free amino groups) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may be derived from inorganic bases 25 such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

In addition to the compounds of the present invention that display ER- β activity, compounds of the present invention can also be employed as intermediates in the synthesis of 30 such useful compounds.

Synthesis

Compounds within the scope of the present invention may be synthesized chemically by means well known in the art. The following Examples are meant to show general synthetic schemes, which may be used to produce many different variations by employing various 5 commercially-available starting materials. These Examples are meant only as guides on how to make some compounds within the scope of the invention, and should not be interpreted as limiting the scope of the invention.

Examples**Example 1 (Route A)****10 -(3-Bromo-4-hydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one**

1,3,5-Trihydroxybenzaldehyde (1.01 g, 6.25 mmol) and 3-bromo-4-hydroxyphenylacetic acid (1.44 g, 6.25 mmol) were suspended in POCl_3 (4 mL). After 1 min, an exothermic reaction occurred. The mixture was allowed to cool to room temperature. Zinc chloride (1M ether solution, 4.7 mmol) was added and the mixture was heated at 75 °C for 1 15 h. After cooling, the mixture was partitioned in ethyl acetate and 1M aqueous HCl. The organic layer was washed with brine and dried with MgSO_4 . Purification on silica gel (MeOH/dichloromethane, gradient) afforded 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone (390 mg) as a tan solid.

To 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone (370 mg) in 20 DMF (5 mL) under nitrogen was added $\text{BF}_3\text{-Et}_2\text{O}$ (0.83 mL, 6.55 mmol) dropwise, followed by methanesulfonyl chloride (0.507 mL, 6.55 mmol). The mixture was stirred at room temperature for 10 min and heated at 55 °C for 30 min. After cooling, the mixture was partitioned in ethyl acetate / 1M aqueous HCl. The organic layer was washed with 1M HCl and brine, and purified by C_{18} HPLC to give the title compound (55 mg).

25 Example 2 (Compound No. 28; Route B)**3-(4-hydroxyphenyl)-7-hydroxy-4-methylcoumarin**

A solution of 2,4-dihydroxyacetophenone (1.1 g, 7.24 mmol), 4-hydroxyphenylacetic acid (1.45 g, 9.5 mmol) and potassium acetate (0.9 g, 9.2 mmol) in acetic anhydride (10 mL) was heated under reflux for 18 h. After cooling, the mixture was poured into ice and water.

30 The solid was filtered, washed with ether and dried under vacuum to give 3-(4-acetoxyphenyl)-7-acetoxy-4-methylcoumarin (1.83 g).


-10-

A suspension of 3-(4-acetoxyphenyl)-7-acetoxy-4-methylcoumarin (500 mg) in THF (10 mL) and 1N aqueous sodium hydroxide (10 mL) was stirred for 1 h. The mixture is acidified to pH = 1 with concentrated HCl and extracted with EtOAc / water. The organic layer was washed with brine and dried over MgSO₄. Evaporation of the solvent and trituration 5 of the residue with ether gave the title compound (140 mg).

The HPLC conditions (HPLC 4.6 x 250 mm C₁₈ 5 µm Vydx 218TP54 column, flow rate: 1.5 mL/min, acetonitrile/water 0.1% TFA linear gradient from 10:90 to 50:50 over 30 min, UV detection: 254 nm) are referred as conditions A.

The HPLC conditions (HPLC 2.1 x 30 mm C₁₈ 3.5 µm Zorbax Rapid Resolution 10 column, flow rate: 0.7 mL/min, water - 0.05% TFA for 0.5 min, then 90% aqueous acetonitrile/water 0.05% TFA linear gradient from 0:100 to 80:20 over 9.5 min, UV detection) are referred as conditions B.

The following compounds were prepared according to these routes, using the relevant starting materials.



15

Table 1.

No.	L ¹	L ²	L ³	L ⁴	R ¹
1	C(=O)	=C-	=CR ⁶ -	O	3,4-dihydroxyphenyl
2	C(=O)	=C-	=CR ⁶ -	O	2-Cl-4-hydroxyphenyl
3	C(=O)	=C-	=CR ⁶ -	O	2-Me-4-hydroxyphenyl
4	C(=O)	=C-	=CR ⁶ -	O	3-F-4-hydroxyphenyl
5	C(=O)	=C-	=CR ⁶ -	O	3-Cl-4-hydroxyphenyl
6	C(=O)	=C-	=CR ⁶ -	O	3-Br-4-hydroxyphenyl
7	C(=O)	=C-	=CR ⁶ -	O	3-allyl-4-hydroxyphenyl
8	C(=O)	=C-	=CR ⁶ -	O	3-Pr-4-hydroxyphenyl

-11-

No.	<u>L</u> ¹	<u>L</u> ²	<u>L</u> ³	<u>L</u> ⁴	<u>R</u> ¹
9	C(=O)	=C-	=CR ⁶ -	O	3-methoxy-4-hydroxyphenyl
10	C(=O)	=C-	=CR ⁶ -	O	3,5-diMe-4-hydroxyphenyl
11	C(=O)	=C-	=CR ⁶ -	O	4-fluorophenyl
12	C(=O)	=C-	=CR ⁶ -	O	3,4-(OCH ₂ O)phenyl
13	C(=O)	=C-	=CR ⁶ -	O	4-aminophenyl
14	C(=O)	=C-	=CR ⁶ -	O	2-naphthyl
15	C(=O)	=C-	=CR ⁶ -	O	3-hydroxyphenyl
16	C(=O)	=C-	=CR ⁶ -	O	2-hydroxyphenyl
17	C(=O)	=C-	=CR ⁶ -	O	2-thiophene
18	C(=O)	=C-	=CR ⁶ -	O	3-thiophene
19	C(=O)	=C-	=CR ⁶ -	O	2-quinolinyl
20	C(=O)	=C-	=CR ⁶ -	O	4-bromophenyl
21	C(=O)	=C-	=CR ⁶ -	O	4-chlorophenyl
22	C(=O)	=C-	=CR ⁶ -	O	4-hydroxyphenyl
23	C(=O)	=C-	=CR ⁶ -	O	4-hydroxyphenyl
24	C(=O)	=C-	=CR ⁶ -	O	3-F-4-hydroxyphenyl
25	C(=O)	=C-	=CR ⁶ -	O	4-hydroxyphenyl
26	C(=O)	-CH-	-CHR ⁶ -	O	4-hydroxyphenyl
27	C(=O)	-CH-	-CHR ⁶ -	CH ₂	4-hydroxyphenyl
28	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
29	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
30	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
31	=CR ⁶ -	=C-	C(=O)	O	2-thiophene
32	C(=O)	=C-	=CR ⁶ -	O	4-hydroxyphenyl
33	C(=O)	=C-	=CR ⁶ -	O	2-F-phenyl
34	C(=O)	=C-	=CR ⁶ -	O	phenyl
35	C(=O)	=C-	=CR ⁶ -	O	phenyl
36	O	=C-	=CR ⁶ -	C(=O)	4-hydroxyphenyl

-12-

<u>No.</u>	<u>L¹</u>	<u>L²</u>	<u>L³</u>	<u>L⁴</u>	<u>R¹</u>
37	CH ₂	-CH-	-CHR ⁶ -	C(=O)	4-hydroxyphenyl
38	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
39	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
40	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
41	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
42	=CR ⁶ -	=C-	C(=O)	O	4-Cl-phenyl
43	=CR ⁶ -	=C-	C(=O)	O	4-hydroxyphenyl
44	C(=O)	=C-	=CR ⁶ -	O	4-isopropoxyphenyl
45	C(=O)	-CH-	-CHR ⁶ -	CH ₂	3-Br-phenyl
46	CH ₂	-CH-	-CHR ⁶ -	O	4-hydroxyphenyl

(Continuation of Table 1)

<u>No.</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>
1	OH	H	OH	H	H
2	OH	H	OH	H	H
3	OH	H	OH	H	H
4	OH	H	OH	H	H
5	OH	H	OH	H	H
6	OH	H	OH	H	H
7	OH	H	OH	H	H
8	OH	H	OH	H	H
9	OH	H	OH	H	H
10	OH	H	OH	H	H
11	OH	H	OH	H	H
12	OH	H	OH	H	H
13	OH	H	OH	H	H
14	OH	H	OH	H	H
15	OH	H	OH	H	H
16	OH	H	OH	H	H

-13-

No.	<u>R</u> ²	<u>R</u> ³	<u>R</u> ⁴	<u>R</u> ⁵	<u>R</u> ⁶
17	OH	H	OH	H	H
18	OH	H	OH	H	H
19	OH	H	OH	H	H
20	OH	H	OH	H	H
21	OH	H	OH	H	H
22	OH	H	OMe	H	H
23	Me	H	OH	H	H
24	H	H	OH	H	H
25	H	H	OH	H	CF ₃
26	OH	H	OH	H	H
27	OH	H	OH	H	H
28	H	H	OH	H	Me
29	H	H	OH	H	Et
30	H	H	H	H	H
31	H	H	OH	H	H
32	OH	H	OH	OMe	H
33	OH	H	OH	H	H
34	OH	H	OH	H	Ph
35	H	H	OH	H	Ph
36	H	H	OH	H	H
37	H	H	OH	H	H
38	H	H	OH	H	H
39	OH	H	OH	H	H
40	H	H	H	OH	H
41	H	OH	H	H	H
42	H	H	OH	H	Me
43	H	H	OH	Me	Me
44	H	H	OH	H	CF ₃
45	H	H	OH	H	H

-14-

No.	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>
46	H	H	OH	H	H

Table 2. Purification, Properties, and Synthetic Route

No.	<u>HPLC min (method)</u>	<u>MS (MH⁺)</u>	<u>ER-β K_i nM</u>	<u>ER-α K_i nM</u>	<u>Synthetic Route</u>
1			2.15	605	*
2	5.76 (B)	305 (³⁵ Cl)	0.55	56	A
3	5.41 (B)	285	1.2	61	A
4	5.62 (B)	289	0.5	74	A
5	6.11 (B)	305 (³⁵ Cl)	1.2	1100	A
6	25.6 (A)	349 (⁷⁹ Br)	1.25	439	A
7	6.72 (B)	311	3.2	>3000	A
8	7.08 (B)	313	0.75	>3000	A
9			143	>3000	*
10	25.4 (A)	299	25	>3000	A
11	6.93 (B)	273	100	>3000	A
12			22	>3000	*
13			6	>3000	*
14	7.86 (B)	305	150	>3000	A
15	5.39 (B)	271	15	900	A
16	5.68 (B)	271	110	>3000	A
17	'H NMR (DMSO-d ₆): 12.59 (s, 1H), 10.99 (s, 1H), 8.88 (s, 1H), 7.63 (m, 2H), 7.14 (m, 1H), 6.44 (s, 1H), 6.27 (s, 1H).		3.3	>3000	A
18	'H NMR (DMSO-d ₆): 12.92 (s, 1H), 10.93 (s, 1H), 8.72 (s, 1H), 8.07 (s, 1H), 7.64 (m, 1H), 7.53 (m, 1H), 6.42 (s, 1H), 6.24 (s, 1H).		17	>3000	A
19	5.26 (B)	306	122	>3000	A
20	7.70 (B)	333 (⁷⁹ Br)	25	>3000	A

-15-

<u>No.</u>	<u>HPLC min (method)</u>	<u>MS (M⁺)</u>	<u>ER-β K_i nM</u>	<u>ER-α K_i nM</u>	<u>Synthetic Route</u>
21	7.55 (B)	289 (³⁵ Cl)	42	>3000	A
22			50	>3000	*
23	5.20 (B)	269	0.5	200	A
24	4.91 (B)	273	3.3	>3000	A
25	6.07 (B)	323	10	321	Note a)
26			3.7	1000	*
27	5.43 (B)	271	5.7	3000	Note b)
28	¹ H NMR (DMSO-d ₆): 10.47 (m, 1H), 9.55 (m, 1H), 7.67 (d, 1H), 7.1-6.7 (m, 6H), 2.22 (m, 3H); MS: 269		12	322	B
29	5.57 (B)	283	4	80	B
30	6.01 (B)	239	140	>3000	B
31	¹ H NMR (DMSO-d ₆): 10.68 (s, 1H), 8.44 (s, 1H), 7.75 (m, 1H), 7.60 (m, 2H), 7.16 (m, 1H), 6.87 (dd, 1H), 6.81 (m, 1H); MS: 245		108	>3000	B
32			33	>3000	*
33	¹ H NMR (DMSO d-6): 12.66 (s, 1H), 10.98 (s, 1H), 8.42 (s, 1H), 7.48 (m, 2H), 7.27 (m, 2H), 6.44 (d, 1H, J= 2.1 Hz), 6.26 (d, 1H, J= 2.1 Hz); MS: 273		50	>3000	A
34			9.5	95	*
35			19	50	*
36			0.33	88	*
37	¹ H NMR (DMSO d-6): 9.61 (s, 1H), 9.52 (s, 1H), 7.26 (d, 1H, J= 2.7 Hz), 7.21-7.13 (m, 3H), 6.99 (dd, 1H, J= 8.1 Hz, J'= 2.7 Hz), 6.71 (d, 2H, J= 8.4 Hz), 3.26 (m, 1H), 3.07-2.80 (m, 3H), 2.64 (m, 1H); MS: 253 (M-H) ⁻		0.73	75	Note c)

-16-

<u>No.</u>	<u>HPLC min (method)</u>	<u>MS (MH⁺)</u>	<u>ER-β K_i nM</u>	<u>ER-α K_i nM</u>	<u>Synthetic Route</u>
38		¹ H NMR (DMSO d-6): 10.52 (s, 1H), 9.64 (s, 1H), 8.03 (s, 1H), 7.55 (m, 3H), 6.85-6.70 (m, 4H); MS: 255	4.9	220	B
39		¹ H NMR (DMSO d-6): 10.63 (s, 1H), 10.33 (s, 1H), 9.60 (s, 1H), 7.95 (s, 1H), 7.50 (d, 2H, J= 8.4 Hz), 6.80 (d, 2H, J= 8.4 Hz), 6.28 (s, 1H), 6.22 (s, 1H); MS: 271	79	>3000	B
40		¹ H NMR (DMSO d-6): 10.18 (s, 1H), 9.73 (s, 1H), 8.08 (s, 1H), 7.60 (d, 2H, J= 8.4 Hz), 7.17 (m, 2H), 7.06 (m, 1H), 6.85 (d, 2H, J= 8.4 Hz); MS: 255	104	>3000	B
41		¹ H NMR (DMSO d-6): 9.72 (s, 2H), 8.05 (s, 1H), 7.58 (d, 2H, J= 8.4 Hz), 7.25 (d, 1H, J= 8.7 Hz), 7.07 (d, 1H, J= 2.7 Hz), 7.00 (dd, 1H, J= 8.4 Hz, J'= 2.7 Hz), 6.84 (d, 2H, J= 8.4 Hz); MS: 255	4.6	3000	B
42		¹ H NMR (DMSO d-6): 10.56 (s, 1H), 7.50 (d, 2H, J= 7.8 Hz), 7.42 (d, 1H, J= 8.7 Hz), 7.33 (d, 2H, J= 7.8 Hz), 6.84 (dd, 1H, J= 7.8 Hz, J'= 2.1 Hz), 6.75 (d, 1H, J= 2.1 Hz), 2.21 (s, 3H); MS: 287 (³⁵ Cl)	51	>3000	B
43		¹ H NMR (DMSO d-6): 10.36 (s, 1H), 9.55 (s, 1H), 7.49 (d, 1H, J= 9 Hz), 7.08 (d, 2H, J= 8.7 Hz), 6.87 (d, 1H, J= 9 Hz), 6.81 (d, 2H, J= 8.7 Hz), 2.21 (s, 3H), 2.19 (s, 3H); MS: 283	24	500	B
44		¹ H NMR (DMSO d-6): 11.11 (s, 1H), 7.93 (d, 1H, J= 8.7 Hz), 7.16 (d, 2H, J= 8.4 Hz), 7.03-6.93 (m, 4H), 4.66 (m, 1H), 1.30 (d, 6H, J= 6Hz); MS: 365	118	3000	Note a)

-17-

No.	HPLC min (method)	MS (MH ⁺)	ER-β K _i nM	ER-α K _i nM	Synthetic Route
45		¹ H NMR (DMSO d-6): 10.39 (s, 1H), 7.78 (d, 1H, J= 8.4 Hz), 7.42 (m, 2H), 7.28 (t, 1H, J= 7.8 Hz), 7.19 (d, 1H, J= 7.8 Hz), 6.75 (dd, 1H, J= 8.4 Hz, J'= 2.4 Hz), 6.69 (d, 1H, J= 2.4 Hz), 3.86 (m, 1H), 3.00 (m, 1H), 2.85 (m, 1H), 2.4-2.1 (m, 2H); MS: 317 (⁷⁹ Br)	116	3000	Note b)
46			2	155	*

* compound is commercially available.

Note a): Prepared according to method A; the cyclization step was done using trifluoroacetic anhydride according to J. Med. Chem. 1992, 35, 3519.

Note b): Prepared by cyclization of the corresponding 2,4-diarylbutyric acid with POCl₃, and 5 subsequent demethylation of the methoxy ethers according to the method developed in J. Org. Chem. 1946, 11, 34.

Note c): Prepared according to Aust. J. Chem. 1978, 31, 1011.

CLAIMS:

1. A method for treating a disease associated with the estrogen receptor- β , comprising the step of administering a therapeutically-effective amount of a compound that satisfies the
5 equation:

$$(K_{iaA}/K_{ibA})/(K_{iaE}/K_{ibE}) > 1,$$

wherein


- 10 K_{iaA} is the K_i value for the agonist in ER- α ;
 K_{ibA} is the K_i value for the agonist in ER- β ;
 K_{iaE} is the K_i value for estrogen in ER- α ; and
 K_{ibE} is the K_i value for estrogen in ER- β .

2. The method according to Claim 1, wherein the compound satisfies the equation:
15 $(K_{iaA}/K_{ibA})/(K_{iaE}/K_{ibE}) > 100.$

3. The method according to Claim 2, wherein the disease to be treated is selected from the group consisting of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer.

4. The method according to Claim 3, wherein the compound has the formula:

20



wherein:

L^1 is $-C(=O)-$, $=C(R^6)-$, $-CH(R^6)-$, O, S, or NR^2 ;

25 L^2 is $=C-$ or $-CH-$;

-19-

L^3 is $=C(R^6)-$, $-CH(R^6)-$ or $-C(=O)-$;

L^4 is $-C(=O)-$, CH_2 , O , S , or NR^a ;

wherein:

when L^1 is $-C(=O)-$, L^2 is CH_2 , O , S , or NR^a ;

5 when L^4 is $-C(=O)-$, L^1 is CH_2 , O , S , or NR^a ;

when L^3 is $-C(=O)-$, L^1 is $=C(R^6)-$ or $-CH(R^6)-$, and L^4 is O or NR^a

when L^1 is $=C(R^6)-$, L^2 is $=C-$;

when L^1 is $-CH(R^6)-$, L^2 is $-CH-$;

when L^3 is $=C(R^6)-$, L^2 is $=C-$; and

10 when L^3 is $-CH(R^6)-$, L^2 is $-CH-$;

R^a is, independently, at each occurrence, H or (C_1-C_5) alkyl;

R^1 is phenyl, substituted phenyl or Het;

R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of $-R^a$, $-OR^a$,

$-SR^a$, $-NR^aR^a$, $-NC(=O)R^a$, $-NS(=O)R^a$, $-NS(=O)_2R^a$, halogen, cyano, $-CF_3$, $-CO_2R^a$, $-C(=O)R^a$,

15 $-C(=O)NHR^a$, nitro, $-S(=O)R^a$ and $-S(=O)_2R^a$;

R^6 is H , (C_1-C_5) alkyl, phenyl or CF_3 ; and

wherein, when L^1 is $-C(=O)-$, and R^2 is hydroxy or hydrogen, and R^3 is hydrogen, and


R^4 is hydroxy, and R^5 is hydrogen, and R^6 is hydrogen then R^1 is not para-phenol; and

any pharmaceutically-acceptable salt thereof.

20 5. The method according to Claim 4, wherein R^1 is Het.

6. The method according to Claim 4, wherein:

R^1 has the structure:



wherein:

25 R^7 is H , Cl or methyl;

-20-


R^8 is Br, Cl, F, R^a , OR^a or allyl;

R^9 is H, OH, NH₂, Br or Cl; and

R^{10} is H or methyl; or

R^8 and R^9 combine to form -OCH₂O-; or

5 R^1 is a substituted or unsubstituted version of one of the following:



10

7. The method according to any one of Claims 6, wherein the disease is Alzheimer's disease or depressive disorders.

8. The method according to Claim 6 wherein R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of R^a , OR^a , NR^a_2 , $NC(=O)R^a$, CF_3 , and halogen.

15 9. The method according to Claim 8 wherein:

R^2 is hydroxyl or hydrogen;


R^3 is hydrogen or methyl;

R^4 is hydroxyl or hydrogen; and

R^5 is hydrogen or hydroxyl.

-21-

10. The method according to Claim 8 wherein L^4 is $-C(=O)-$.
11. The method according to Claim 8 wherein L^3 is $-C(=O)-$.
12. The method according to Claim 8 wherein L^1 is $-C(=O)-$.
13. The method according to Claim 9 wherein R^1 is an unsubstituted version of



5

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number
WO 00/62765 A3

(51) International Patent Classification⁷: A61K 31/35.
31/38. 31/47. A61P 9/00, 25/22, 25/24, 19/02, 19/10,
35/00

(21) International Application Number: PCT/GB00/01380

(22) International Filing Date: 11 April 2000 (11.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/129,901 16 April 1999 (16.04.1999) US


(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BARLAAM, Bernard, Christophe [FR/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US). PISER, Timothy, Martin [US/US]; 1800 Concord Pike, Wilmington, DE 19850-5437 (US).

(74) Agent: PHILLIPS, Neil, Godfrey, Alasdair; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(54) Title: ESTROGEN RECEPTOR-β LIGANDS



(57) Abstract: A method for treating a disease associated with the estrogen receptor-β, comprising the step of administering a therapeutically - effective amount of a compound that satisfies the equation: $(K_{ia\alpha}/K_{i\beta\alpha})/(K_{ie\beta}/K_{i\beta\beta}) > 1$, optionally having the general structure (I) including among other flavones, isoflavones, coumarins and chromanones for treating a disease selected from the group consisting of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01380

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7 A61K31/35 A61K31/38 A61K31/47 A61P9/00 A61P25/22 A61P25/24 A61P19/02 A61P19/10 A61P35/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 7 A61K A61P					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
X	EP 0 135 172 A (TAKEDA CHEMICAL INDUSTRIES LTD) 27 March 1985 (1985-03-27) abstract page 1 -page 2; claims 1-4; examples 1-4 ---				1
X	US 5 733 926 A (GORBACH SHERWOOD L) 31 March 1998 (1998-03-31) abstract column 1, line 6 -column 2, line 38; claims 1-18 ---				1
					-/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents :					
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed			"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search			Date of mailing of the international search report		
25 January 2001			17.04.01		
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016			A. Jakobs		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VINSON J A ET AL: "PLANT FLAVONOIDS, ESPECIALLY TEA FLAVONOLS, ARE POWERFUL ANTIOXIDANTS USING AN IN VITRO OXIDATION MODEL FOR HEART DISEASE" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 43, no. 11, 1 November 1995 (1995-11-01), pages 2800-2802, XP000537899 ISSN: 0021-8561 abstract; figure 1; table 1 page 2802, column 1, paragraph 4 ---	1
X	ANDERSON J J B ET AL: "BIPHASIC EFFECTS OF GENISTEIN ON BONE TISSUE IN THE OVARIECTOMIZED, LACTATING RAT MODEL (44243)" PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, US, ACADEMIC PRESS INC, NEW YORK, vol. 217, no. 3, 1998, pages 345-350, XP000915041 ISSN: 0037-9727 abstract page 345, column 1 -page 346, column 1, paragraph 2; figure 1 ---	1
X	J GELLER ET AL: "GENISTEIN INHIBITS THE GROWTH OF HUMAN-PATIENT BPH AND PROSTATE CANCER IN HISTOCULTURE" PROSTATE, US, WILEY-LISS, NEW YORK, NY, vol. 2, no. 34, 1 February 1998 (1998-02-01), pages 75-79, XP002077078 ISSN: 0270-4137 abstract ---	1
X	M C BOSLAND ET AL: "INHIBITION OF HUMAN PROSTATE CANCER CELL PROLIFERATION BY GENISTEIN" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, NEW YORK, NY, no. 38, 1 March 1997 (1997-03-01), page 262 XP002077080 abstract ---	1
X	WO 98 50026 A (KELLY GRAHAM EDMUND ;NOVOGEN INC (US)) 12 November 1998 (1998-11-12) abstract page 8, line 9 -page 10, line 10 ---	1
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01380

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 44920 A (MEDINA JORGE HORACIO ;PALADINI ALEJANDRO CONSTANTINO (AR); UNIV ST) 15 October 1998 (1998-10-15) abstract ---	1
A	BINDAL, RAJESHWAR D. ET AL: "1,2-Bis(4-hydroxyphenyl)-3,4-dihydro-6-hydroxynaphthalene, a photofluorogenic ligand for the estrogen receptor" PHOTOCHEM. PHOTOBIOOL. (1986), 43(2), 121-6, XP000980188 the whole document ---	1-13
A	MCCAGUE, RAYMOND ET AL: "Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy]phenyl]-5H- benzocycloheptene, a nonisomerizable analog of tamoxifen. X-ray crystallographic studies" J. MED. CHEM. (1986), 29(10), 2053-9, XP002121531 the whole document ---	1-13
A	EP 0 729 951 A (LILLY CO ELI) 4 September 1996 (1996-09-04) abstract ---	1-13
A	EP 0 835 867 A (LILLY CO ELI) 15 April 1998 (1998-04-15) abstract -----	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/01380

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-13 (all partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 00/01380

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0135172	A 27-03-1985	JP 60048924 A DE 3430799 A IT 1179067 B		16-03-1985 14-03-1985 16-09-1987
US 5733926	A 31-03-1998	AU 724813 B AU 7844898 A EP 0971695 A WO 9825588 A		28-09-2000 03-07-1998 19-01-2000 18-06-1998
WO 9850026	A 12-11-1998	AU 7017198 A EP 0979074 A		27-11-1998 16-02-2000
WO 9844920	A 15-10-1998	EP 0973516 A		26-01-2000
EP 0729951	A 04-09-1996	US 5998401 A AT 180776 T AU 694837 B AU 4573296 A BR 9600821 A CA 2170337 A CN 1137525 A,B CN 1261534 A CZ 9600581 A DE 69602638 D DE 69602638 T DK 729951 T ES 2132841 T FI 960889 A GR 3030407 T JP 8268881 A NO 960772 A NZ 286072 A PL 312829 A SG 55098 A TR 960838 A US 5574190 A US 5567712 A		07-12-1999 15-06-1999 30-07-1998 05-09-1996 23-12-1997 29-08-1996 11-12-1996 02-08-2000 11-09-1996 08-07-1999 21-10-1999 23-06-1999 16-08-1999 29-08-1996 30-09-1999 15-10-1996 29-08-1996 28-10-1996 02-09-1996 21-12-1998 21-10-1996 12-11-1996 22-10-1996
EP 0835867	A 15-04-1998	CA 2217571 A JP 10204028 A US 5916916 A		10-04-1998 04-08-1998 29-06-1999